Herpes simplex virus type 2 growth and latency reactivation by cocultivation are inhibited with antisense oligonucleotides complementary to the translation initiation site of the large subunit of ribonucleotide reductase (RR1)

Antisense and Nucleic Acid Drug Development

Volumn 10, Issue 2, 2000, Pages 77-85

  Aurelian, L ^a   Smith, C C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; RIBONUCLEOTIDE REDUCTASE;

ANIMAL CELL; ARTICLE; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; TRANSLATION INITIATION; VIROGENESIS; VIRUS INHIBITION; VIRUS LATENCY; VIRUS REACTIVATION;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; MARTES PENNANTI;

EID: 0034015110     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.2000.10.77     Document Type: Article

References (66)

1. ALI, M.A. (1995). The 140-kDa RR1 protein from both HSV-1 and HSV-2 contains an intrinsic protein kinase activity capable of autophosphorylation but it is transphosphorylation defective. Virology 207, 409-416.
2. ARNOLD, L.J., Jr., (1994). The development of oligonucleotides containing chirally pure methylphosphonates as therapeutic agents. First Int. Antisense Conference of Japan, Kyoto, Japan, Dec 4-7, Abstract OP-31.
3. AURELIAN, L., ed. (1990). Herpesviruses, the Immune System and AIDS. (Kluwer Academic Publishers, Boston).
4. AURELIAN, L. (1998). Herpes simplex virus type 2: Unique biological properties include neoplastic potential mediated by the PK domain of the large subunit of ribonucleotide reductase. Front. Biosci. 3, d237-249. PubMed No: 9459654. URL:http://bioscience.org/ 1998/v3/d/aurelian/list.htm
5. AURELIAN, L., KOKUBA, H., and SMITH, C.C. (1999). Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10). Vaccine 17, 1951-1963.
6. AURELIAN, L., TERZANO, P., SMITH, C.C., CHUNG, T.D., SHAMSUDDIN, A., COSTA, S., and ORLANDI, C. (1989). Amino-terminal epitope of herpes simplex virus type 2 ICP10 protein as a molecular diagnostic marker for cervical intraepithelial neoplasia. Cancer Cells 7, 187-191.
7. BOURNE, N., STANBERRY, L.R., CONNELLY, B.L., KURAWADALA, J., STRAUSS, S.E., and KRAUSE, P.R. (1994). Quantity of latency-associated transcript produced by herpes simplex virus is not predictive of the frequency of experimental recurrent genital herpes. J. Infect. Dis. 169, 84-88.
8. BRUNI, R., and ROIZMAN, B. (1998). Herpes simplex virus 1 regula tory protein ICP22 interacts with a new cell cycle-regulated factor and accumulates in a cell cycle-dependent fashion in infected cells. J. Virol., 72, 8525-8531.
9. CHUNG, T.D., WYMER, J.P., SMITH, C.C., KULKA, M., and AURELIAN, L. (1989). Protein kinase activity associated with the large subunit of the herpes simplex virus type ribonucleotide reductase (ICP10). J. Virol. 63, 3389-3398.
10. CONNER, J., MACFARLANE, J., LANKINEN, H., and MARSDEN, H. (1992). The unique N-terminus of the herpes simplex virus type 1 large subunit is not required for ribonucleotide reductase activity. J. Gen. Virol. 73, 103-112.
11. COOPER, J., CONNER, J., and CLEMENTS, J.B. (1995). Characterization of the novel protein kinase activity present in the R1 subunit of herpes simplex virus ribonucleotide reductase. J. Virol. 69, 4979-4985.
12. DESAI, P., RAMAKRISHNAN, R., LIN, Z.W., OSAK, B., GLORIOSO, J.C., and LEVINE, M. (1993). The RR1 gene of herpes simplex virus type 1 is uniquely trans-activated by ICP0 during infection. J. Virol. 67, 6125-6135.
13. DROLET, B.S., PERNG, G.C., COHEN, J., SLANINA, S.M., YUKHT, A., NESBURN, A.B., and WECHSLER, S.L. (1998). The region of the herpes simplex virus type 1 LAT gene involved in spontaneous reactivation does not encode a functional protein. Virology 242, 221-232.
14. FAWL, R.L., and ROIZMAN, B. (1993). Induction of reactivation of herpes simplex virus in murine sensory ganglia in vivo by cadmium. J. Virol. 67, 7025-7031.
15. FENG, C.P., KULKA, M., and AURELIAN, L. (1993). The GGTCA palindrome and cognate cellular factors in trans-regulation of human immunodeficiency virus long terminal repeat by herpes simplex virus. J. Gen. Virol. 74, 715-723.
16. FENG, C.P., KULKA, M., SMITH, C.C., and AURELIAN, L. (1996). Herpes simplex virus-mediated activation of human immunodeficiency virus is inhibited by oligonucleoside methylphosphonates that target immediate-early mRNAs 1 and 3. Antisense Nucleic Acid Drug Dev. 6, 25-35.
17. FLEMING, D.T., McQUILLAN, G.M., JOHNSONS, R.E., NAHMIAS, A.J., ARAL, S.O., LEE, F.K., and St. LOUIS, M.E. (1997). Herpes simplex virus type 2 in the United States, 1976 to 1994. N. Engl. J. Med. 337, 1105-1111.
18. GAO, W.Y., HANES, R.N., VAZQUEZ-PADUA, M.A., STEIN, C.A., COHEN, J.S., and CHENG, Y.C. (1990). Inhibition of herpes simplex virus type 2 growth by phosphorothioate oligodeoxynucleotides. Antimicrob. Agents Chemother. 34, 808-812.
19. GOLDSTEIN, D.J., and WELLER, S.K. (1988a). Factor(s) present in the herpes simplex virus type-1 infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: Characterization of an ICP6 deletion mutant. Virology 166, 41-51.
20. GOLDSTEIN, D.J., and WELLER, S.K. (1988b). Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol. 62, 196-205.
21. HO, D.Y., and MOCARSKI, E.S. (1989). Herpes simplex virus latent RNA (LAT) is not required for latent infection in the mouse. Proc. Natl. Acad. Sci. USA 86, 7596-7600.
22. HONESS, R.W., and ROIZMAN, B. (1974). Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. J. Virol. 14, 8-19.
23. HOOK, E.W.D., CANNON, R.O., NAHMIAS, A.J., LEE, F.F., CAMPBELL, C.H.J., GLASSER, D., and QUINN, T.C. (1992). Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals [see Comments]. J. Infect. Dis. 165, 251-255.
24. HUNTER, J.C.R., SMITH C.C., and AURELIAN, L. (1995). The HSV-2 LA-1 oncoprotein is a member of a novel family of serine/threonine receptor kinases. Int. J. Oncol. 7, 515-522.
25. IDOWU, A.D., FRASER-SMITH, E.B., PAFFENBERGER, K.L., and HERMAN, R.C. (1992). Deletion of herpes simplex virus type 1 ribonucleotide reductase gene alters virulence and latency in vitro. Antiviral Res. 17, 145-156.
26. INGEMARSON, R., and LANKINEN, H. (1987). The herpes simplex virus type 1 ribonucleotide reductase is a tight complex of the type alpha 2 and beta 2 composed of 40 K and 140 K proteins, of which the latter shows multiple forms due to proteolysis. Virology 156, 417-422.
27. JACOBSON, J.G., LEIB, D.A., GOLDSTEIN, D.J., BOGRAD, C.L., SCHAFFER, P.A., WELLER, S.K., and COEN, D.M. (1989). A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology 173, 276-283.
28. JACQUEMONT, B., VERRIER, B., EPSTEIN, A.L., and MACHUCA, I. (1984). Expression of immediate-early genes in herpes simplex virus type 1-infected XC cells: Lack of ICP22 (68 K) polypeptide. J. Gen. Virol. 65, 1331-1340.
29. JIN, P., and RINGERTZ, N.R. (1990). Cadmium induces transcription of proto-oncogenes c-jun and c-myc in rat L6 myoblasts. J. Biol. Chem. 265, 14061-14064.
30. KEAN, J.M., KIPP, S.A., MILLER, P.S., KULKA, M., and AURELIAN, L. (1995). Inhibition of herpes simplex virus replication by antisense oligo-2′-O-methylribonucleoside methylphosphonates. Biochemistry 34, 14617-14620.
31. KEET, I.P., LEE, F.K., VAN GRIENSVEN, G.J., LANGE, J.M., NAHMIAS, A., and COUTINHO, R.A. (1990). Herpes simplex virus type 2 and other genital ulcerative infections as a risk factor for HIV-1 acquisition. Genitourin. Med. 66, 330-333.
32. + cell: Effect of coinfection on infectious HSV-2 and HIV-1 replication. J. AIDS Res. Hum. Retrovir. 6, 641-647.
33. KULKA, M., SMITH, C.C., AURELIAN, L., FISHELEVICH, R., BLAKE, K., MILLER, P.S., and TS'O, P.O.P. (1989). Site specificity of the inhibitory effect of oligonucleotide methylphosphonates complementary to the acceptor splice junction of HSV-1 pre-mRNA 4. Proc. Natl. Acad. SCi. USA 86, 6868-6872.
34. KULKA, M., SMITH, C.C., LEVIS, J., FISHELEVICH, R., HUNTER, J.C., CUSHMAN, C.D., MILLER, P.S., TS'O, P.O., and AURELIAN, L. (1994). Synergistic antiviral activities of oligonucleoside methylphosphonates complementary to herpes simplex virus type 1 immediate-early mRNAs 4, 5, and 1. Antimicrob. Agents Chemother. 38, 675-680.
35. KULKA, M., WACHSMAN, M., MIURA, S., FISHELEVICH, S., MILLER, P.S., TS'O, P.O., and AURELIAN, L. (1993). Antiviral effect of oligo(nucleoside methylphosphonates) complementary to the herpes simplex virus type 1 immediate-early mRNAs 4 and 5. Antiviral Res. 20, 115-130.
36. LAFFERTY, W.M., REMINGTON, C., WINTER, A., FAHNLANDER, A., and COREY, L. (1985). Natural history of concomitant pharyngeal and genital HSV infection: Influence on viral type and anatomic site on recurrence rates. Clin. Res. 33, 408A.
37. LANKINEN, H., TELFORD, E., MACDONALD, D., and MARSDEN, H. (1989). The unique N-terminal domain of the large subunit of herpes simplex virus ribonucleotide reductase is preferentially sensitive to proteolysis. J. Gen. Virol. 70, 3159-3169.
38. LEKSTROM-HIMES, J.A., PESNICAK, L., and STRAUSS, S.E. (1998). The quantity of latent viral DNA correlates with the relative rates at which herpes simplex virus types 1 and 2 cause recurrent genital herpes outbreaks. J. Virol. 72, 2760-2764.
39. LEOPARDI, R., WARD, P.L., OGLE, W.O., and ROIZMAN, B. (1997). Association of herpes simplex virus regulatory protein ICP22 with transcriptional complexes containing EAP, ICP4, RNA poly- merase II, and viral DNA requires posttranslational modification by the U(L)13 protein kinase. J. Virol. 71, 1133-1139.
40. LIEB, D.A., BOGARD, C.L., KOSZ-VNENCHAK, M., HICKS, K.A., COEN, D.M., KNIFE, D.M., and SCHAFFER, P.A. (1989). A deletion mutant of the latency-associated transcript of herpes simplex virus type 1 reactivates from the latent state with reduced frequency. J. Virol. 63, 2893-2900.
41. LONG, M.C., LEONG, V., SCHAFFER, P.A., SPENCER, C.A., and RICE, S.A. (1999). ICP22 and the UL13 protein kinase are both required for herpes simplex virus-induced modification of the large subunit of RNA polymerase II. J. Virol. 73, 5593-5604.
42. MAGGIONCALDA, J., MEHTA, A., SU, Y.H., FRASER, N.W., and BLOCK, T.M. (1996). Correlation between herpes simplex virus type 1 rate of reactivation from latent infection and the number of infected neurons in trigeminal ganglia. Virology 225, 72-81.
43. MILLER, P.S. (1998). Oligonucleoside methylphosphonates. Synthesis and properties. In: Applied Oligonucleotide Technology. C.A. Stein and A. Krieg, eds. (John Wiley & Sons, New York), pp. 3-22.
44. MILLER, P.S., and HAMMA, T. (1999). Studies of anti-HIV oligonucleotides that contain alternating methylphosphonate/phosphodiester linkages. Antisense Nucleic Acid Drug Dev. 9, 367-370.
45. NELSON, J.W., ZHU, J., SMITH, C.C., KULKA, M., and AURELIAN, L. (1996). ATP and SH3 binding sites in the protein kinase of the large subunit of herpes simplex virus type 2 of ribonucleotide reductase (ICP10). J. Biol. Chem. 271, 17021-17027.
46. OGLE, W.O., and ROIZMAN, B. (1999). Functional anatomy of herpes simplex virus 1 overlapping genes encoding infected-cell protein 22 and US 1.5 protein. J. Virol. 73, 4305-4315.
47. PENG, T., HUNTER, J.R.C., and NELSON, J.W. (1996). The novel protein kinase of the RR1 subunit of herpes simplex virus has autophosphorylation and transphosphorylation activity that differs in its ATP requirements for HSV-1 and HSV-2. Virology 216, 184-196.
48. PERNG, G.C., GHIASAI, H., SLANINA, S.M., NESBURN, A.G., and WECHSLER, S.L. (1996). The spontaneous reactivation function of the herpes simplex virus type 1 LAT gene resides completely within the first 1.5 kilobases of the 8.3-kilobase primary transcript. J. Virol. 70, 976-984.
49. POFFENBERGER, K.L., IDOWU, A.D., FRASER-SMITH, E.B., RAICHLEN, P.E., and HERMAN, R.C. (1994). A herpes simplex virus type 1 ICP22 deletion mutant is altered for virulence and latency in vivo. Arch. Virol. 139, 111-119.
50. POFFENBERGER, K.L., RAICHLEN, P.E., and HERMAN, R.C. (1993). In vitro characterization of a herpes simplex virus type 1 ICP22 deletion mutant. Virus Genes 7, 171-186.
51. PURVES, F.C., OGLE, W.O., and ROIZMAN, B. (1993). Processing of the herpes simplex virus regulatory protein alpha 22 mediated by the UL13 protein kinase determines the accumulation of a subset of alpha and gamma mRNAs and proteins in infected cells. Proc. Natl. Acad. Sci. USA 90, 6701-6705.
52. RICE, S.A., LONG, M.C., LAM, V., SCHAFFER, P.A., and SPENCER, C.A. (1995). Herpes simplex virus immediate-early protein ICP22 is required for viral modification of host RNA polymerase II and establishment of the normal viral transcription program. J. Virol. 69, 5550-5559.
53. SAWTELL, N.M. (1997). Comprehensive quantification of herpes simplex virus latency at the single-cell level. J. Virol. 71, 5423-5431.
54. SEARS, A.E., HALLIBURTON, I.W., MEIGNIER, B., SILVER, S., and ROIZMAN, B. (1985). Herpes simplex virus 1 mutant deleted in the alpha 22 gene: Growth and gene expression in permissive and restrictive cells and establishment of latency in mice. J. Virol. 55, 338-346.
55. SMITH, C.C., and AURELIAN, L. (1997). The large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is associated with the virion tegument and has PK activity. Virology 234, 235-242.
56. SMITH, C.C., AURELIAN, L., REDDY, M.P., MILLER, P.S., and TS'O, P.O.P. (1986). Antiviral effect of an oligonucleoside methylphosphonates complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNA 4 and 5. Proc. Natl. Acad. Sci. USA 83, 2787-2791.
57. SMITH, C.C., KULKA, M., WYMER, J.P., CHUNG, T.D., and AURELIAN, L. (1992). Expression of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for virus growth and neoplastic transformation. J. Gen. Virol. 73, 1417-1428.
58. SMITH, C.C., PENG, T., KULKA, M., and AURELIAN, L. (1998). The PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is involved in IE gene transcription and virus growth. J. Virol. 72, 9131-9141.
59. TAL-SINGER, R., LASNER, T.M., PODRZUCKI, W., SKOKOTAS, A., LAEARY, J.J., BERGER, S.L., and FRASER, N.W. (1997). Gene expression during reactivation of herpes simplex virus type 1 from latency in the peripheral nervous system is different from that during lytic infection of tissue cultures. J. Virol. 71, 5268-5276.
60. THOMAS, S.K., GOUGH, G., LATCHMAN, D.S., and COFFIN, R.S. (1999). Herpes simplex virus latency-associated transcript encodes a protein which greatly enhances virus growth, can compensate for deficiencies in immediate-early gene expression, and is likely to function during reactivation from virus latency. J. Virol. 73, 6618-6625.
61. VALYI-NAGY, T., DESHMANE, S., DILLNER, A., and FRASER, N.W. (1991). Induction of cellular transcription factors in trigeminal ganglia of mice by corneal scarification, herpes simplex virus type 1 infection, and explanation of trigeminal ganglia. J. Virol. 65, 4142-4152.
62. WACHSMAN, M., LUO, J.H., AURELIAN, L., and PAOLETTI, E. (1992). Protection from herpes simplex virus type 2 is associated with T cells involved in delayed-type hypersensitivity that recognize glycosylation-related epitopes on glycoprotein D. Vaccine 10, 447-454.
63. WANG, K., PESNICAK, L., and STRAUSS, S.E. (1997). Mutations in the 5′ end of the herpes simplex virus type 2 latency-associated transcript (LAT) promoter affect LAT expression in vivo but not the rate of spontaneous reactivation of genital herpes. J. Virol. 71, 7903-7910.
64. WYMER, J.P., CHUNG, T.D., CHANG, Y.N., HAYWARD, G.S., and AURELIAN, L. (1989). Identification of immediate-early type cis-response elements in the promoter for the ribonucleotide reductase large subunit from herpes simplex virus type 2. J. Virol. 63, 2773-2784.
65. YOSHIKAWA, T., HILL, J.M., STANBERRY, L.R., BOURNE, N., KURAWADWALA, J.F., and KRAUSE, P.R. (1996). The characteristic site-specific reactivation phenotype of HSV-1 and HSV-2 depend upon the latency-associated transcript region. J. Exp. Med. 184, 659-664.
66. ZHU, J., and AURELIAN, L. (1997). AP-1 cis-response element are involved in basal expression and Vmw110 transactivation of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP0). Virology 231, 301-312.